Join to View Full Profile
200 1st St SWRochester, MN 55905
Phone+1 507-284-2511
Dr. Storandt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Storandt is an oncologist based in Rochester, MN. He completed his medical degree in 2021 at the University of North Dakota School of Medicine and Health Sciences. Following his residency in Internal Medicine from 2021 to 2024, he is currently pursuing a fellowship in Hematology and Medical Oncology at the Mayo Clinic College of Medicine and Science. He has published several research studies in reputable journals, including The Oncologist and Cancers, with works focusing on therapies for hepatocellular carcinoma and the prediction of cancer recurrence. His research has been cited by other publications, reflecting engagement with his contributions in the field.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2024 - 2027
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2021 - 2024
University of North Dakota School of Medicine and Health SciencesClass of 2021
Certifications & Licensure
MN State Medical License 2022 - 2025
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers.Amit Mahipal, Leslie Bucheit, Nicole Zhang, Reagan M Barnett, Michael H Storandt
The Oncologist. 2025-03-10 - Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations.Michael H Storandt, Qian Shi, Cathy Eng, Christopher Lieu, Thomas George
Cancers. 2025-02-28 - 4 citationsAtezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study.Michael H Storandt, Tyler J Zemla, Kanchi Patell, Nikolas Naleid, Jennifer J Gile
The Oncologist. 2024-11-04
Press Mentions
Mayo Clinic Comprehensive Cancer Center to Highlight Key Studies at ASCO 2024May 31st, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
